Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection

The purpose of this study was to determine the effect of dapsone on platelet count in patiente with human immunodeficiency virus (HTV)-related autoimmune thrombocytopenia. PATIENTS AND METHODS: Eleven patiente with HIV-related thrombocytopenia received dapsone (50 to 125 mg/day) for 2 to 43 months. Patients with the acquired immunodeficiency syndrome were not enrolled. Of the 11 patiente, six developed platelet counts above 50 × 10 9/L and did not require any other specific therapy. No significant side effects were observed. We conclude that dapsone may be effective in some patiente with HIV-related thrombocytopenia.